TITLE

EARLY EXPERIENCE WITH FIBRINOLYSIN

AUTHOR(S)
Cliffton, Eugene E.
PUB. DATE
August 1959
SOURCE
Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p244
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In this paper attempts have been made to bring together the apparently divergent opinions of several groups of investigators. The differences seem to be largely matters of semantics and variations in methods and techniques of measurement of activity and in material available for testing rather than valid difference of opinion about the mechanisms or effectiveness of fibrinolysin. One common method of determining unitage and reporting results would solve many of our problems. Fibrinogen and inhibitor concentration is of great importance in the results of treatment with fibrinolysin. It has been established that plasmin (fibrinolysin) can dissolve thrombi in animals, and there is strong evidence that this occurs in patients. It is believed that the pyrogenic reaction to SK is the main disadvantage to fibrinolysin therapy. The dangers of hemorrhage, sensitivity reaction or spread of infection are not a serious possibility. Further attempts to develop other activators or to purify plasmin are certainly indicated. The possibility of enhancing the effect of plasmin with heparin or other agents should be actively investigated. Treatment of 76 cases with thrombotic or embolic processes has been reported. Excellent results have been obtained with venous thromboses of all stages of development. In a few cases of arterial thrombi or emboli good results have been obtained, most commonly with local treatment. With 4 mg per kg of plasmin in the dog there is significant loss of fibrinogen and some change in prothrombin. With 6 mg per kg these changes are more marked. However, in the pig, which has a very high concentration of inhibitor for human plasmin, there is practically no effect with 6.3 mg of plasmin per kg. In patients with high inhibitor levels the same effect is seen.
ACCESSION #
16388348

 

Related Articles

  • A MILESTONE IN THROMBOEMBOLIC DISEASE. Halpern, Alfred; Samuels, Saul S. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p243 

    Looks into developments in the study of thromboembolic disease. Therapeutic potential of a fibrinolytic enzyme; Investigation of a particular type of fibrnolysin in many human thromboembolic states; Discussion by a group of investigators of their experiences with fibrinolysin.

  • THROMBOLYSIS WITH FIBRINOLYSIN IN CEREBRAL ARTERIAL OCCLUSION; THE ROLE OF ANGIOGRAPHY. Sussman, Bernard J.; Fitch, Thomas S. P. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p268 

    Nine patients with demonstrable cerebral or carotid occlusions have been treated with fibrinolysin. The results of treatment have been interpreted on the basis of follow-up angiograms or postmortem studies. Favorable results marked by vascular clearing have been obtained in 4 cases. Three of...

  • FIBRINOLYSIN THERAPY OF THROMBOEMBOLISM: THREE YEARS' EXPERIENCE. Sheffer, Albert L.; Lisker, Samuel; Nemir Jr., Paul // Angiology;May1961, Vol. 12 Issue 5, p165 

    The clinical evaluation of 67 patients treated with fibrinolysin is presented. Thirty-three cases reported previously are added for follow-up purposes. Thrombophlebitis, pulmonary embolism, vascular surgery and ophthalmologic experience are described. There are a few encouraging examples in each...

  • THE USE OF FIBRINOLYSIN IN THE PREVENTION OF THROMBUS FORMATION IN SMALL ARTERY ANASTOMOSES. Engler, Harold S.; Christopher, Phillip; Moretz, William H. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p259 

    A study of the use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses is reported. Under the conditions of this experiment no beneficial effect was observed. Our experience with the use of fibrinolysin in 9 vascular operations is also described briefly. With the...

  • Fibrinolysis: The Key to New Pathogenetic Mechanisms. Zorio, Esther; Gilabert-Estellés, Juan; España, Francisco; Ramón, Luis A.; Cosín, Raul; Estellés, Amparo // Current Medicinal Chemistry;2008, Vol. 15 Issue 9, p923 

    The fibrinolytic system includes a broad spectrum of proteolytic enzymes with physiological and pathophysiological functions in several processes, such as haemostatic balance, tissue remodeling, tumor invasion, angiogenesis and reproduction. The main enzyme of the plasminogen activator system is...

  • Evolutionary Trend of Thrombolytics. Kumar, Anmol; Pulicherla, K. K.; Ram, K. Seetha; Rao, K. R. S. Sambasiva // International Journal of Bio-Science & Bio-Technology;Dec2010, Vol. 2 Issue 4, p51 

    Thrombolytic drugs have been used in the clinical arena to treat a wide variety of venous and arterial thromboembolic disorders which are a main cause of death. Thrombolytic molecules are plasminogen activators that convert the inactive plasminogen to the active proteolytic enzyme plasmin which...

  • Plasminogen-related.  // Encyclopedic Reference of Cancer;2001, p701 

    A definition of the term "plasminogen-related protein" is presented. It refers to a protein that shares structural similarity and evolutionary relationship with plasminogen.

  • Urokinase stimulates inflammatory response in damaged vascular wall during in vivo arterial remodeling. O. Plekhanova; M. Menshikov; M. Solomatina; E. Ratner; V. Tkachuk; Ye. Parfyonova // Bulletin of Experimental Biology & Medicine;Jan2008, Vol. 145 Issue 1, p10 

    Abstract  Perivascular application of urokinase to the ballooned artery promoted the growth of neointima and constrictive remodeling of the vessel and stimulated the inflammatory response in the damaged vascular wall in vivo. Recombinant tissue plasminogen activator did not induce these...

  • THE TREATMENT OF PULMONARY EMBOLISM WITH FIBRINOLYSIN. Sheffer, Albert L.; Israel, Harold L. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p292 

    An attempt has been made to evaluate fibrinolysin in 33 patients treated for pulmonary embolism or related thrombolic diseases. Six cases of pulmonary embolism are presented in detail. The results suggest that fibrinolysin by itself may not be effective in preventing recurrent embolism. However,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics